2025-09-28 - Analysis Report
Okay, here's an analysis of UnitedHealth Group Inc. (UNH) based on the data you provided. I'll provide the analysis in English with a focus on clear numerical summaries and interpretations.

**Report on UnitedHealth Group Inc. (UNH)**

**0. Overview**

This report analyzes the current state of UnitedHealth Group Inc. (UNH) based on recent performance data, technical indicators, news, analyst opinions, and financial information.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** UNH
*   **Company:** UnitedHealth Group Inc. - A diversified health care company providing a wide range of health benefits and services.
*   **UNH Cumulative Return:** -18.63%
*   **VOO (S&P 500) Cumulative Return:** 66.41%
*   **Disparity:**
    *   **Current:** -66.0%
    *   **Range (Min/Max):** -86.4 / 20.5
    *   **Relative Disparity:** 19.1
    *   *Interpretation:* UNH has significantly underperformed the S&P 500. The relative disparity suggests UNH's current underperformance is near the lower end of its historical range compared to the S&P 500.

*   **Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha   | Beta   | Cap(B) |
| ---------- | -------- | -------- | ------- | ------ | ------ |
| 2015-2017  | 52.0%    | 52.0%    | 43.0%   | -0.0   | 199.7  |
| 2016-2018  | 46.0%    | 70.2%    | 47.0%   | -0.0   | 225.6  |
| 2017-2019  | 47.0%    | 70.2%    | 42.0%   | 0.0    | 266.2  |
| 2018-2020  | -34.0%   | 81.4%    | -60.0%  | 0.2    | 317.6  |
| 2019-2021  | 10.0%    | 81.4%    | -19.0%  | 0.8    | 454.8  |
| 2020-2022  | -1.0%    | 81.4%    | -15.0%  | 0.8    | 480.2  |
| 2021-2023  | 22.0%    | 78.0%    | 4.0%    | 0.3    | 476.8  |
| 2022-2024  | -29.0%   | 78.5%    | -42.0%  | 0.3    | 458.1  |
| 2023-2025  | -65.0%   | 78.5%    | -100.0% | 0.5    | 311.6  |

*   *Analysis:*  The table highlights a significant decline in recent years (2018-2025) compared to previous periods.  CAGR has declined dramatically, MDD is consistently high, and Alpha is significantly negative, indicating substantial underperformance relative to its benchmark on a risk-adjusted basis. Beta has increased slightly but remains relatively low. Market Cap has also shown recent decline.

**2. Recent Stock Price Movement**

*   **Last Price:** 344.08
*   **Previous Close:** 345.56
*   **Change:** -0.43
*   **5-day Moving Average:** 346.48
*   **20-day Moving Average:** 335.15
*   **60-day Moving Average:** 300.51

*   *Analysis:* The stock price closed slightly lower than the previous day.  The price is below the 5-day moving average but above the 20-day and 60-day moving averages. This indicates a possible short-term downtrend, but still above the longer term trend.

**3. Technical Indicators and Outlook**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 64.39
*   **PPO:** -0.39
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) (Cash Ratio: 0% on 2025-09-16)
*   **20-day Relative Disparity Change:** 1.6 (+, Short-term increase)
*   **Expected Return (vs. S&P 500):** -86.4%

*   *Analysis:*
    *   The high MRI suggests the overall market environment is conducive to investment.
    *   The RSI of 64.39 is approaching overbought territory (above 70).
    *   PPO indicates a slightly bearish trend.
    *   The positive change in relative disparity is a positive sign of short-term improvement.
    *   The expected return is highly negative, indicating significant expected underperformance relative to the S&P 500 over a long-term investment horizon. The Hybrid signal indicates a strong buy recommendation based on the current analysis.

**4. Recent News & Significant Events**

*   **Key Headlines:**
    *   Catalysts Shaping UnitedHealth's Narrative
    *   Healthcare Stocks That Can Win Amidst Washington's Disruption
    *   UnitedHealth vs. Molina: Poised for Comeback?
    *   Bretton Fund: UnitedHealth Group Incorporated (UNH) had a Quarter from Hell
    *   Plus Therapeutics Seals Partnership with United Healthcare

*   *Analysis:* The news is mixed. There are articles discussing potential catalysts and winners in the healthcare space, but also articles highlighting challenges and underperformance.  The "Quarter from Hell" headline is concerning. The partnership news could be a positive catalyst.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (~1.96 on a 1-5 scale)
*   **Number of Opinions:** 24
*   **Target Price:**
    *   **Average:** 342.58
    *   **High:** 626.00
    *   **Low:** 198.00
*   **Recent Rating Changes:** No changes indicated.

*   *Analysis:*  Analysts generally have a "Buy" rating on UNH. However, the wide range in target prices suggests significant uncertainty about the stock's future performance. The current price is near the average target price.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue       |
| ---------- | ---- | ------------- |
| 2025-08-11 | 3.76 | 111.62 B$   |
| 2025-05-07 | 6.9  | 109.58 B$   |
| 2024-11-04 | 6.56 | 100.82 B$   |
| 2024-08-09 | 4.58 | 98.86 B$    |
| 2025-08-11 | 4.58 | 98.86 B$    |

*   *Analysis:*  Revenue has generally been increasing, while EPS is showing volatility with a recent drop, but in average is stable. It is important to verify why that values are equal for two different dates.

**6. Financial Information**

*   **Revenue and Profitability:**

| Quarter    | Revenue     | Profit Margin |
| ---------- | ----------- | ------------- |
| 2025-06-30 | $111.62B   | 17.93%        |
| 2025-03-31 | $109.58B   | 21.70%        |
| 2024-12-31 | $100.81B   | 21.14%        |
| 2024-09-30 | $100.82B   | 22.84%        |
| 2024-06-30 | $98.86B    | 22.31%        |

*   **Capital and Profitability:**

| Quarter    | Equity      | ROE       |
| ---------- | ----------- | --------- |
| 2025-06-30 | $94.72B    | 3.60%     |
| 2025-03-31 | $95.04B    | 6.62%     |
| 2024-12-31 | $92.66B    | 5.98%     |
| 2024-09-30 | $94.53B    | 6.41%     |
| 2024-06-30 | $89.36B    | 4.72%     |

*   *Analysis:*  Revenue has been consistently increasing. Profit margins have decreased recently. Equity has fluctuated. ROE has decreased significantly.

**7. Overall Summary and Conclusion**

UnitedHealth Group (UNH) is currently facing challenges.  While revenue is growing, profitability (both profit margin and ROE) is declining. The stock has significantly underperformed the S&P 500, and the technical indicators are mixed. Recent news contains both positive and negative elements.  Analysts maintain a generally positive outlook, but with a wide range of price targets, which introduces uncertainty about future performance. While the MRI signals it is a good time to invest, the expected return signals a negative performance, so, caution is advised.

**Recommendation:** Given the mixed signals, a neutral to slightly cautious stance is warranted.  Investors should closely monitor UNH's earnings, news flow, and progress on addressing its challenges before making any investment decisions.
